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to 5.5% per year,2,3 with approximately 7 in 10 
deaths related to cardiovascular causes.
It is therefore evident that to reduce the bur‑
den of cardiovascular complications, the man‑
agement of patients with AF should not be lim‑
ited to the appropriate prescription of OAC but 
should include a proactive holistic approach to 
cardiovascular risk factors and comorbidities. 
However, a structured clinical approach has been 
only recently proposed4 and indicated by CHEST 
guidelines as an appropriate way to manage AF 
patients.5
This approach, namely the Atrial fibrillation 
Better Care (ABC) pathway6 (Figure 1), includes 
3 components: A stands for avoid stroke with 
anticoagulation, B, for better symptom manage‑
ment, and C refers to cardiovascular and other 
comorbidity risk optimization.
The management of patients with atrial fibril‑
lation (AF) has improved in the last decade af‑
ter the introduction of direct oral anticoagu‑
lants (DOACs), which enlarged therapeutic op‑
tions for thrombo prophylaxis in this patient 
population. Thus, DOACs showed at least sim‑
ilar efficacy to warfarin, with a safer profile re‑
garding major hemorrhages, in particular intra‑
cranial bleeding. However, a large proportion of 
patients with AF is still not receiving an appro‑
priate oral anticoagulation (OAC), with residu‑
al thrombotic risk.
In addition, there are some complications not 
strictly related to AF that are not, or only par‑
tially, preventable by OAC, such as cardiovascu‑
lar death attributed to heart failure and death 
due to noncardiovascular causes.1 The reported 
incidence rate of death in patients with AF is up 
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Figure 1 The ABC pathway 
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; 
CAD, coronary artery disease; DOAC, direct oral anticoagulant; HF, heart failure; OAC, oral anticoagulation; TTR, time in 
therapeutic range
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OAC is the physician’s preference, emphasizes 
the role of medical doctors in the optimization 
of thromboprophylaxis.11
The study also revealed the suboptimal man‑
agement of AF in elderly patients, such as those 
aged 80 years or older.9 This is concerning be‑
cause elderly patients represent a high ‑risk sub‑
group in whom the risk of stroke and cardiovas‑
cular events is particularly evident. In addition, 
DOACs seem to be effective and safe also in el‑
derly patients, being a suitable therapeutic op‑
tion for these patients, avoiding the need to as‑
sess international normalized ratio.12
The management of comorbidities may be par‑
ticularly challenging in the AF population, consid‑
ering that these patients usually have a high num‑
ber of cardio metabolic diseases, such as metabol‑
ic syndrome and heart failure. The BALKAN ‑AF 
study showed a suboptimal management of co‑
morbidities in patients with AF. For instance, 
more than 30% of patients with heart failure were 
not receiving a therapy including an ACE inhibitor 
or angiotensin receptor blocker, and more than 
30% of patients with prevalent coronary artery 
disease not receiving statin therapy.
The implementation of the ABC pathway has 
prognostic implications. Thus, recent observa‑
tions from a post ‑hoc analysis from the AFFIRM 
(Atrial Fibrillation Follow‑up Investigation of 
Rhythm Management) study,13 from the real‑
‑life ATHERO ‑AF (Atherosclerosis in Atrial Fi‑
brillation) study cohort14 and from the database 
of the National Health Insurance Sharing Service 
in South Korea,15 showed a reduced rate of differ‑
ent complications in patients adherent to the ABC 
pathway. A clear advantage of this approach re‑
lies on including modifiable risk factors, such as 
anticoagulation quality, blood pressure control, 
and AF ‑related symptoms, which would there‑
fore allow us to modify the individual risk of pa‑
tients over time.
In conclusion, patients with AF are still not op‑
timally managed; the advantages of appropriate 
anticoagulation may be lost if other comorbidi‑
ties are not well addressed leaving patients with 
a residual cardiovascular risk. A structured inte‑
grated management of patients with AF (ie, ABC 
pathway) should be implemented.
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The A component means the optimization of 
stroke prevention with OAC. In patients treated 
with warfarin this component consists of main‑
taining a stable high quality of anticoagulation, as 
assessed by the time in therapeutic range at val‑
ues higher than 65% to 70%.7,8 In patients treat‑
ed with DOACs, the optimization of OAC is rep‑
resented by the prescription of the appropriate 
dosage of a DOAC based on patient characteris‑
tics. The second component of the ABC pathway, 
B, implies the need for assessing the presence 
of symptoms related to AF. The simple Europe‑
an Heart Rhythm Association score may be used 
for this purpose. The assessment of AF ‑related 
symptoms may help decisions regarding rate and 
rhythm control. The last component, C, includes 
a proactive management of associated lifestyle 
risk factors (ie, unhealthy diet and low physical 
activity) management and control of cardiomet‑
abolic risk factors.
The recently published analysis by Kozieł et al9 
on patients included in the BALKAN ‑AF sur‑
vey provides interesting insights on trends in 
the management of AF patients in the East Eu‑
rope. As correctly stated by the authors, patients 
from this region were underrepresented in clini‑
cal trials. According to the ABC pathway, less than 
50% of patients were optimally treated. Predictors 
of adherence to the ABC management were: liv‑
ing in the capital city (odds ratio [OR], 1.23; 95% 
CI, 1.03–1.46; P = 0.02), treatment by cardiolo‑
gist (OR, 1.34; 95% CI, 1.08–1.66; P = 0.01), ar‑
terial hypertension (OR, 2.2; 95% CI, 1.74–2.77; 
P <0.001), diabetes mellitus (OR, 1.28; 95% CI, 
1.05–1.57; P = 0.01), and multimorbidity (≥2 con‑
ditions) (OR, 1.85; 95% CI, 1.43–2.38; P <0.001). 
Conversely, older age (≥80 years) (OR, 0.61; 95% 
CI, 0.48–0.76; P <0.001) and history of bleeding 
(OR, 0.5; 95% CI, 0.33–0.75; P = 0.001) were asso‑
ciated with lower adherence to the ABC pathway.9
After analyzing in more detail some aspects of 
the results from the present study, it becomes ev‑
ident that the use of OAC is still low; thus even in 
patients with an indication to OAC (ie, CHA2DS2‑
‑VASc ≥2) the authors reported a prevalence of 
OAC use of 59.9%, with a still high use of anti‑
platelet drugs and 8.5% of patients not receiv‑
ing any antithrombotic treatment.9 In the OAC 
group, at the time of the survey, the use of DO‑
ACs was still very low. This low rate of anticoag‑
ulation may be due to several reasons, includ‑
ing difficult access to healthcare services in non‑
capital cities and high cost of DOAC treatment 
compared with standard warfarin. Furthermore, 
as also happens in other countries, prescription 
of DOACs may be reserved to specific specialties 
(ie, cardiology and internal medicine) or regulat‑
ed by specific rules, which hinders the increase 
in DOAC use. However, in keeping with a pre‑
vious study,10 referral to a cardiology specialist, 
compared with primary care setting, was associ‑
ated with an increased rate of OAC prescription. 
This finding, together with evidence suggesting 
that the most common reason for not receiving 
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